Sept. 26 (UPI) -- Humanetics Corporation is to develop solid-dosage formulations of BIO 300, a drug to mitigate the toxicities of exposure to radiation.
The drug, administered orally, is in clinical development by the Minnesota-based firm and is aimed for deployment to military personnel and first responders.